Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
2024 Readers' Choice Awards
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Class of 2025
Hammarskjold High School
Superior Collegiate and Vocational Institute
Westgate Collegiate & Vocational Institute
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Merus N.V. - Common Shares
(NQ:
MRUS
)
56.41
+1.42 (+2.58%)
Streaming Delayed Price
Updated: 12:48 PM EDT, Jul 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merus N.V. - Common Shares
< Previous
1
2
3
4
5
6
Next >
10 Analysts Have This to Say About Merus
September 14, 2023
Via
Benzinga
AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst
September 11, 2023
On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients
Via
Benzinga
Merus to Participate in Upcoming Investor Conferences
August 31, 2023
From
Merus N.V.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 21, 2023
August 21, 2023
Via
Benzinga
Where Merus Stands With Analysts
August 10, 2023
Via
Benzinga
Expert Ratings for Merus
July 24, 2023
Via
Benzinga
Analyst Expectations for Merus's Future
June 30, 2023
Via
Benzinga
Where Merus Stands With Analysts
May 18, 2023
Via
Benzinga
Merus Announces Pricing of Public Offering of Common Shares
August 09, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus N.V. Announces Proposed Public Offering of Common Shares
August 09, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update
August 07, 2023
From
Merus N.V.
Via
GlobeNewswire
Recap: Merus Q1 Earnings
May 04, 2023
Via
Benzinga
Analyst Boosts Merus Price Target As AACR Updates Meaningfully De-Risk Its Head & Cancer Therapy
April 18, 2023
Via
Benzinga
The Latest Analyst Ratings for Merus
April 05, 2023
Via
Benzinga
Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023
July 28, 2023
From
Merus N.V.
Via
GlobeNewswire
Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration
July 05, 2023
From
Merus N.V.
Via
GlobeNewswire
Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer
June 29, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer
June 15, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference 2023
May 31, 2023
From
Merus N.V.
Via
GlobeNewswire
7 Stocks That Wall Street Analysts Are Loving in May
May 21, 2023
Though not perfect, an analyst rating can indicate where institutional investor sentiment lies; here are seven stocks that analysts love.
Via
InvestorPlace
Merus Announces Financial Results for the First Quarter 2023 and Provides Business Update
May 04, 2023
From
Merus N.V.
Via
GlobeNewswire
Why Glory Star New Media Group Shares Are Trading Higher By 122%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 18, 2023
Gainers Glory Star New Media Group Holdings Limited (NASDAQ: GSMG) shares jumped 122% to $1.07 after the company announced the signing of a $60 million strategic investment with two institutional...
Via
Benzinga
Ericsson, Johnson & Johnson, Goldman Sachs And Other Big Stocks Moving Lower On Tuesday
April 18, 2023
U.S. stocks traded lower, with the Dow Jones dropping over 100 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)
April 17, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus' Petosemtamab Abstract Hits Upside Scenario For Overall Response Rate, Duration Of Response: Analyst
April 14, 2023
Via
Benzinga
Merus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR Annual Meeting 2023
April 14, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 and Provides a Program and Regulatory Update
April 14, 2023
From
Merus N.V.
Via
GlobeNewswire
What To Expect When Merus Presents Petosemtamab Data Update At AACR
April 06, 2023
Via
Benzinga
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
March 15, 2023
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.
Via
InvestorPlace
Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2023
March 14, 2023
Poster presentation: Tuesday, April 18, 2023, 1:30-5:30 p.m. ET
From
Merus N.V.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.